PT-141 is a cyclic heptapeptide that binds all five melanocortin receptors and prefers some of them, which is what "selective" means in this family. No melanocortin ligand is exclusive to one subtype. The useful question is never whether a compound is selective but how large the ratio is, measured against which other subtype, and by which assay — and those three qualifiers change the answer more than the compound does.
Five receptors doing unrelated jobs
The melanocortin system is unusual in how little its subtypes have in common functionally despite close structural similarity. The family divides by tissue and role rather than by sequence distance, which is why a ligand that cannot discriminate between two of them produces effects in two unrelated systems at once.
| Receptor | Principal distribution | Why it matters for a ligand |
|---|---|---|
| MC1R | Melanocytes | Pigmentation; the off-target in most melanocortin work |
| MC2R | Adrenal cortex | Responds essentially only to ACTH; rarely engaged by analogues |
| MC3R | Central nervous system, periphery | Often co-engaged with MC4R and hard to separate from it |
| MC4R | Central nervous system | The subtype most melanocortin analogue work is aimed at |
| MC5R | Exocrine tissue | Lowest-affinity target for most analogues |
MC2R is the outlier: it responds to ACTH and largely ignores the shorter melanocortin peptides, so analogue work in practice concerns four receptors rather than five. The separation that is genuinely difficult is MC3R from MC4R, and a compound described as MC4R-selective is almost always selective against MC1R while retaining meaningful MC3R activity.
What the structure contributes
PT-141 is seven residues with three modifications, and each one does identifiable work. The core is the His-Phe-Arg-Trp motif that runs through the whole family — the minimum unit the receptors recognise, which is why every melanocortin analogue contains some version of it.
The lactam bridge. A covalent bond between an aspartate side chain and a lysine side chain closes the molecule into a ring. This is the single most consequential modification: it removes most of the conformational freedom a linear peptide has, so the molecule presents the recognition motif in a fixed geometry rather than sampling thousands. Cyclisation buys both selectivity and protease resistance for the same structural reason — an enzyme needs an extended backbone to thread through its active site, and a ring does not offer one.
The D-phenylalanine. Substituting the mirror-image form at one position flips the side chain's orientation relative to the backbone. Mammalian proteases are built for L-residues and read a D-centre poorly, so the substitution blocks cleavage at that point while also fixing the motif's presentation.
The N-terminal acetyl and the norleucine. Capping the free amine removes the substrate aminopeptidases recognise. Norleucine in place of methionine removes the sulphur atom that would otherwise be the molecule's most oxidation-prone site — a stability decision that incidentally makes the compound easier to store in solution than its unmodified relatives.
How does PT-141 relate to Melanotan-2?
It is a metabolite that became a compound in its own right. Bremelanotide is the deamidated form of MT-2: where MT-2 terminates in an amide, PT-141 terminates in a free carboxyl, and that single change shifts the profile away from MC1R and toward MC4R. The three compounds form a gradient — MT-1 weighted to MC1R, MT-2 broad, PT-141 weighted to MC4R — rather than a progression in which each supersedes the last. Which one suits a given question depends on which receptor the work is aimed at.
Why is selectivity expressed as a ratio?
Because an affinity figure alone cannot tell you whether a compound discriminates. A ligand with nanomolar affinity at MC4R is only selective if its affinity elsewhere is substantially weaker, and "substantially" needs a number. The ratio of two EC50 or Ki values carries that information; either figure on its own does not. A tenfold ratio and a thousandfold ratio describe very different molecules and both get called selective.
The further complication is that the two figures being divided must come from the same assay format. Binding affinity and functional potency measure different events — whether the ligand occupies the receptor, and whether occupancy produces a signal — and a compound can rank differently on the two. Ratios assembled from figures taken out of separate papers with separate cell lines and separate readouts are not comparable, which is the most common way a selectivity claim turns out to be weaker than it appears.
Why is MC3R so hard to separate from MC4R?
Because the two subtypes recognise the same core motif with similar geometry, so a ligand shaped to fit one tends to fit the other. The modifications that buy selectivity against MC1R — which differs more substantially — do comparatively little between MC3R and MC4R. This has a direct consequence for reading reported data: a result attributed to MC4R engagement in a tissue expressing both subtypes has not isolated either one. Separating them generally requires a knockout model or a subtype-specific antagonist rather than a selective agonist, and which of those a given experimental format permits is the practical constraint.
Does a cyclic peptide still need careful handling?
Yes, and the ring changes which risks apply rather than removing them. Protease resistance is genuinely improved. But the tryptophan in the recognition motif is a photo-oxidation site that cyclisation does nothing about, so amber glass and dark storage remain the sensible default. Adsorption to container surfaces is likewise unaffected by cyclisation and is the dominant loss mechanism at low working concentrations — a problem of surface chemistry, not of backbone stability.
Reading the literature on this family
Three habits make the melanocortin literature easier to interpret. First, check which receptor subtypes were actually tested; a compound reported as selective against MC1R may simply never have been assayed at MC3R or MC5R. Second, check the species, because melanocortin receptor pharmacology differs between rodent and human orthologues more than the sequence similarity suggests. Third, check whether the readout was binding or function, since the two support different claims.
None of this is specific to PT-141 — it is how any receptor-family literature has to be read. The family simply makes the point unusually clearly, because five receptors with a shared recognition motif guarantee that every ligand is a compromise and the only real question is which compromise.
What does the certificate establish for a cyclic peptide?
Mass confirms composition and the bridge together, since cyclisation costs a water molecule and the ring is therefore 18 daltons lighter than the linear chain of the same residues. That is a detectable difference and a genuinely useful one: it distinguishes closed from unclosed material. What mass does not establish is that the bridge formed between the intended pair of side chains, which is a general limitation wherever a molecule can close in more than one way. Lot documents for our material are searchable on the lot verification page.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
